Enteral fish oil supplementation in the resolution of parenteral nutrition associated cholestasis.

OBJECTIVE To analyze safety, tolerance and efficacy of enteral omega-3 fatty acids (FAs) in the resolution of Parenteral Nutrition Associated Cholestasis (PNAC) and postnatal growth among preterm neonates. STUDY DESIGN This is a single center retrospective case-control study of all neonates born less than 32 weeks of gestation and developed PNAC (Direct bilirubin >2 mg/dl). Infants who received enteral omega-3 FAs supplementation (1 g/Kg/d) served as cases and were compared with gestational age, gender and direct bilirubin level matched controls who did not receive enteral omega-3 FAs supplementation. RESULTS A total of 48 infants were analyzed, 24 who received enteral omega-3 fatty acids were matched with 24 controls. The omega-3 FAs and control groups were similar in gestational age (weeks) and birth weight (gram). Overall there were no differences between the two groups in infants' demographics or clinical characteristics including risk factors for the development of PNAC. Infants who received enteral omega-3 FAs had significantly fewer days of cholestasis (p = 0.025) and a higher average daily weight gain (grams/day) (p = 0.011) than their controls. In a linear regression analysis with days of cholestasis as the dependent variable and Ursodeoxycholic acid (UDCA) and Omega-3 FAs as independent variables, enteral omega-3 FAs remained associated with a shorter duration of cholestasis, p < 0.001. CONCLUSION Enteral fish oil is inexpensive, safe & well tolerated in preterm neonates with no contraindications to enteral feeding. Enteral omega-3 FAs are easy to administer and help in rapid resolution of PNAC while promoting postnatal weight gain in preterm infants.

[1]  K. Calkins,et al.  A Neonatologist's Perspective: Is the Quest for an "Ideal" Lipid Emulsion Over? , 2018, JPEN. Journal of parenteral and enteral nutrition.

[2]  Ann N Biesboer,et al.  A Product Review of Alternative Oil-Based Intravenous Fat Emulsions. , 2016, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[3]  R. Gibson,et al.  Targeting inflammation in the preterm infant: The role of the omega-3 fatty acid docosahexaenoic acid , 2016 .

[4]  G. Gourley,et al.  Cholestasis in Preterm Infants. , 2016, Clinics in perinatology.

[5]  Ying-kui Yang,et al.  Molecular impact of omega 3 fatty acids on lipopolysaccharide-mediated liver damage. , 2015, Journal of pediatric surgery.

[6]  V. Kapoor,et al.  Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants. , 2015, The Cochrane database of systematic reviews.

[7]  Ji Hee Kim,et al.  Parenteral fish oil-containing lipid emulsions may reverse parenteral nutrition-associated cholestasis in neonates: a systematic review and meta-analysis. , 2015, The Journal of nutrition.

[8]  T. O'Shea,et al.  Randomized controlled trial of early enteral fat supplement and fish oil to promote intestinal adaptation in premature infants with an enterostomy. , 2014, The Journal of pediatrics.

[9]  S. Eaton,et al.  Incidence, prevention, and treatment of parenteral nutrition-associated cholestasis and intestinal failure-associated liver disease in infants and children: a systematic review. , 2014, JPEN. Journal of parenteral and enteral nutrition.

[10]  Hau D. Le,et al.  Intravenous fish oil lipid emulsion promotes a shift toward anti-inflammatory proresolving lipid mediators. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[11]  K. Setchell,et al.  Phytosterols Promote Liver Injury and Kupffer Cell Activation in Parenteral Nutrition–Associated Liver Disease , 2013, Science Translational Medicine.

[12]  S. Abrams,et al.  High rates of resolution of cholestasis in parenteral nutrition-associated liver disease with fish oil-based lipid emulsion monotherapy. , 2013, The Journal of pediatrics.

[13]  G. Zaloga,et al.  Steroidal Compounds in Commercial Parenteral Lipid Emulsions , 2012, Nutrients.

[14]  P. Calder.  Mechanisms of action of (n-3) fatty acids. , 2012, The Journal of nutrition.

[15]  Y. Finkel,et al.  Improved outcome in neonatal short bowel syndrome using parenteral fish oil in combination with ω-6/9 lipid emulsions. , 2012, JPEN. Journal of parenteral and enteral nutrition.

[16]  E. Huang,et al.  Enteral Fish Oil for Treatment of Parenteral Nutrition‐Associated Liver Disease in Six Infants with Short‐Bowel Syndrome , 2011, Pharmacotherapy.

[17]  Hau D. Le,et al.  Comparison of 5 intravenous lipid emulsions and their effects on hepatic steatosis in a murine model. , 2008, Journal of pediatric surgery.

[18]  E. Tomsits,et al.  Safety and Efficacy of a Lipid Emulsion Containing a Mixture of Soybean Oil, Medium-chain Triglycerides, Olive Oil, and Fish Oil: A Randomised, Double-blind Clinical Trial in Premature Infants Requiring Parenteral Nutrition , 2010, Journal of pediatric gastroenterology and nutrition.

[19]  W. D. Jackson,et al.  Elimination of soybean lipid emulsion in parenteral nutrition and supplementation with enteral fish oil improve cholestasis in infants with short bowel syndrome. , 2010, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[20]  Hau D. Le,et al.  The essentiality of arachidonic acid and docosahexaenoic acid. , 2009, Prostaglandins, leukotrienes, and essential fatty acids.

[21]  C. Valim,et al.  Safety and Efficacy of a Fish-Oil–Based Fat Emulsion in the Treatment of Parenteral Nutrition–Associated Liver Disease , 2008, Pediatrics.

[22]  C. Serhan,et al.  Anti-inflammatory and proresolving lipid mediators. , 2008, Annual review of pathology.

[23]  Anna L. Ells,et al.  The International Classification of Retinopathy of Prematurity revisited. , 2005, Archives of ophthalmology.

[24]  P. Tsao,et al.  Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. , 2004, The Journal of pediatrics.

[25]  T. Babineau,et al.  Incidence, prognosis, and etiology of end-stage liver disease in patients receiving home total parenteral nutrition. , 1999, Surgery.

[26]  J. Vanderhoof,et al.  Dietary lipids influence intestinal adaptation after massive bowel resection. , 1999, Journal of pediatric gastroenterology and nutrition.

[27]  A. Coran,et al.  An analysis of factors contributing to the development of total parenteral nutrition-induced cholestasis. , 1989, JPEN. Journal of parenteral and enteral nutrition.

[28]  E. Bancalari,et al.  Bronchopulmonary dysplasia. , 2001, American journal of respiratory and critical care medicine.

[29]  R. Nelson,et al.  Intrahepatic cholestasis associated with parenteral nutrition in premature infants. , 1979, Pediatrics.